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Abstract
Background. Recently, we identified a microduplication in
chromosomal band 1q21.1 encompassing the CHD1L/
ALC1 gene encoding a chromatin-remodelling enzyme in
congenital anomalies of the kidneys and urinary tract (CA-
KUT) patient.
Methods. To explore the role of CHD1L in CAKUT, we
screened 85 CAKUT patients for mutations in the CHD1L
gene and performed functional analyses of the three heter-
ozygous missense variants detected. In addition, we quan-
titatively determined CHD1L expression in multiple human
fetal and adult tissues and analysed expression of CHD1L
protein in human embryonal, adult and hydronephrotic kid-
ney sections.
Results. Two of three novel heterozygous missense var-
iants identified in three patients were not found in >400
control chromosomes. All variants lead to amino acid sub-
stitutions in or near the CHD1L macro domain, a poly-
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ADP-ribose (PAR)-binding module interacting with PAR
polymerase 1 (PARP1), and showed decreased interaction
with PARP1 by pull-down assay of transfected cell lysates.
Quantitative messenger RNA analysis demonstrated high
CHD1L expression in human fetal kidneys, and levels were
four times higher than in adult kidneys. In the human
embryo at 7–11 weeks gestation, CHD1L immunolocalized
in the early ureteric bud and the S- and comma-shaped
bodies, critical stages of kidney development. In normal
postnatal sections, CHD1L was expressed in the cytoplasm
of tubular cells in all tubule segments. CHD1L expression
appeared higher in the hydronephrotic kidney of one pa-
tient with a hypofunctional CHD1L variant than in normal
kidneys, recapitulating high fetal levels.
Conclusion. Our data suggest that CHD1L plays a role in
kidney development and may be a new candidate gene for
CAKUT.
Keywords: CAKUT; CHD1L; expression pattern; hypofunctional
variant; kidney development
Introduction
Renal tract malformations can occur at the level of the kidney
(e.g. aplasia, hypoplasia, dysplasia with and without cysts or
duplex kidney), collecting system (e.g. hydronephrosis or hy-
droureter), bladder [e.g. vesicoureteral reflux (VUR)] or ure-
thra (e.g. posterior urethral valves) and are subsumed by the
term congenital anomalies of the kidneys and urinary tract
(CAKUT). CAKUT comprise ~15% of all congenital anoma-
lies detected prenatally and are found in>250 syndromes and
in more than one-third of chromosome aberrations [1]. Among
these are disorders like the chromosome 22q11.2 deletion and
the 22q11.2 microduplication syndromes caused by microde-
letion or microduplication of chromosomal region 22q11.2,
suggesting that in certain genes both a loss-of-function and a
gain-of-function may lead to CAKUT [2–4].
A number of developmental genes, such as EYA1 and
SIX1 causing autosomal dominant (AD) branchio-oto-renal
syndrome [5, 6], HNF1B/TCF2 associated with AD renal
cysts and diabetes syndrome [7], and PAX2 causing AD
renal-coloboma syndrome [8], have been implicated in the
pathogenesis of CAKUT [9].
To screen for novel chromosomal regions and genes asso-
ciated with CAKUT pathogenesis, we recently performed
genome-wide array-based comparative genomic hybridisation
in 30 children with various CAKUT phenotypes and extrare-
nal symptoms [10]. In a patient presenting with renal hypo-
plasia, proximal ureteric stenosis and additional anomalies, we
detected a duplication of 2.73 Mb in 1q21.1 [10]. Among the
genes duplicated was CHD1L (syn.: ALC1, amplified in liver
cancer 1), which encodes the chromodomain helicase DNA-
binding protein 1-like protein. CHD1L belongs to the Snf2
family of helicase-related ATP-hydrolyzing proteins and
contains a helicase-like region, which is similar to that of other
members of the Snf2-like group, such as Snf2, Iswi, Chd1 and
CHD7 [11]. ATPases of this family often combine a helicase
domain with motifs that mediate selective recognition of pro-
tein modifications. In CHD1L, this is a macro domain, which
is an ADP-ribose/poly-ADP-ribose (PAR)-binding module
[12].CHD1Lhas been implicated as an oncogene with a major
impact in hepatocellular carcinoma development [13–15] and
has been identified as a chromatin-remodelling enzyme that
interacts with PAR and catalyses PAR polymerase
1 (PARP1)-stimulated nucleosome sliding [16, 17].
Chromatin-remodelling and -modifying enzymes are pre-
dicted to play key roles in differentiation, development and
tumour pathogenesis via effects on chromatin structure and
accessibility [18, 19]. Mutations in CHD7, a gene structur-
ally related to CHD1L, cause CHARGE syndrome, which
includes renal developmental anomalies [20–22]. Therefore,
in this study, we screened 85 CAKUT patients for mutations
in the CHD1L gene and performed functional analyses of the
three heterozygous missense variants identified. In addition,
we quantitatively determined CHD1L expression in multiple
human fetal and adult tissues and analysed expression of
CHD1L protein in human embryonal, adult and hydroneph-
rotic kidney sections. Our data provide evidence for a role of
CHD1L in kidney development and for CHD1L mutations
in the anomalies of the renal tract.
Materials and methods
Patients
The mutation analysis was approved by the ethics committee of the Medical
Faculty of the University of Heidelberg, Germany, and informed assent and/
or consent was obtained from the patients and/or parents as appropriate.
Eighty-five patients presenting with different CAKUT phenotypes, defined
by clinical and renal sonographic assessment, were screened for CHD1L
mutations. The patients presented with one or more of the following
CAKUT phenotypes: kidney agenesis (6 patients), kidney hypoplasia (17
patients), dysplastic kidneys (39 patients), medullary cystic kidney disease
(3 patients) and duplex kidney (11 patients). Nine patients showed ureteral
anomalies: proximal ureteral stenosis (1 patient) and megaureter/hydroneph-
rosis (8 patients). Twenty-four patients presented with VUR. Posterior ure-
thral valves were identified in eight patients. In three patients, heterozygous
missense variants were detected in the CHD1L gene.
Patient 1. The boy was the first child of non-consanguineous healthy
parents. Renal abnormalities are not known in the family. While the kidney
ultrasound of the mother during pregnancy did not disclose any abnormality,
the father was not available for examination by renal ultrasound. The ante-
natal story of the patient was uneventful, and prenatal ultrasound did not
disclose any abnormality. The boy was born at term with weight (3750 g)
and length (50 cm) within the normal range and without dysmorphic fea-
tures. A febrile urinary tract infection (UTI) occurred at age 4 months, which
led to the diagnosis of a hypodysplastic right kidney with right-sided grade
III–IV and left-sided grade II VUR demonstrated by renal ultrasound and
micturating cysto-urethrography (MCUG). While no further UTI occurred,
growth of the right kidney was impaired. At the age of 6 years, the kidney
was small for age (volume 34 mL, <3rd percentile), whereas the contrala-
teral kidney showed compensatory hypertrophy (volume 100 mL, >97th
percentile). Blood pressure and urine analysis were normal, in particular no
leucocyturia or erythrocyturia, no glucosuria and no pathological protein
excretion were detected. The child exhibited normal psychomotor and
somatic development.
Patient 2. The boy is Albanian and was born in Kosovo after an uneventful
pregnancy. The parents were unrelated and healthy with normal renal mor-
phology on the ultrasound scan. During the first year of life, the patient
developed repeated episodes of febrile UTI. Clinical workup revealed a
severe CAKUT phenotype with bilateral massive hydronephrosis due to
obstructive megaureters. He received bilateral pyelostomy at 18 months of
age. The further clinical course was complicated by repeated UTIs leading to
nephrectomy of the left kidney at age 2.5 years. The ureteropelvic drainage of
the right kidney was switched to a cutaneous ureterostomy at the age of 5
years when the family moved to Germany. At that time, advanced chronic
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renal failure [estimated glomerular filtration rate (GFR) 23 mL/min/
1.73m2], uraemic bone disease and growth failure (height 14 cm, <3rd
percentile) were diagnosed. Further findings were unilateral cryptorchid-
ism and subglottic stenosis, presumed secondary to repeated and pro-
longed mechanical ventilation. Renal failure gradually progressed and
renal replacement therapy was initiated at the age of 13 years. Right-sided
nephrectomy and excision of the hydroureter were performed at the time
of renal transplantation at the age of 16 years. Histopathological workup
showed atrophy of the renal parenchyma, chronic tubulointerstitial in-
flammation and chronic ureteritis.
Patient 3. The boy was referred for clinical examination at 3 weeks of
age with severe renal insufficiency (estimated GFR 17 mL/min/1.73m2).
Ultrasound revealed bilateral hypodysplasia of the kidneys. No VUR was
detected by MCUG. Extrarenal organ malformations were not observed.
At the age of 12 months, cystoscopy revealed a posterior urethral valve
with membranous stenosis of the urethra and a trabeculated bladder. The
posterior urethral valve was subsequently excised. During the following
8 years, renal function declined to a GFR <10 mL/min/1.73m2 and
peritoneal dialysis was started at 9 years of age. At the age of 10 years,
the patient received a cadaveric kidney transplant with immediate graft
function.
Materials
All immunohistochemistry was performed on formalin-fixed paraffin-
embedded sections. Samples included (i) phenotypically normal human
kidney samples from chemically induced terminations of pregnancy
between 7 and 11 weeks of gestation (n ¼ 7), collected by the Wellcome
Trust and Medical Research Council-funded Human Developmental
Biology Resource at the UCL Institute of Child Health, London, UK.
Informed consent to analyse these samples was obtained from the mothers
involved, and use was approved by the Joint University College London/
University College Hospital Committee on the Ethics of Human Research.
(ii) Normal postnatal kidneys (n ¼ 4) from autopsies of children who had
died at a mean age of 3.5 years (range: 20 months to 8 years) from causes
not associated with kidney disease, provided by the Department of For-
ensic Medicine of the University of Rostock, Germany. Use of these
samples was approved by the ethics committee of the University of
Rostock. (iii) Kidney and ureteric specimens from Patient 2, who was
nephrectomized at time of transplantation, was provided by the Pathology
Department of the University of Marburg, Germany.
Sequence analysis of CAKUT patients
Genomic DNA samples were obtained from peripheral blood of patients
and blood donors (controls). Twenty-four primer pairs were designed to
amplify 23 coding exons and all adjacent splice sites, the 5#-untranslated
region (5#-UTR) and the 3#-untranslated region (3#-UTR) of the CHD1L
gene by standard polymerase chain reaction (PCR). The entire coding
region including the splice sites at the exon–intron boundaries and the
5#- and 3#-UTR was screened for mutations in 61 CAKUT patients by
direct sequencing using the Big-Dye Terminator v1.1 Sequencing Kit (Ap-
plied Biosystems Deutschland GmbH, Darmstadt, Germany) and an
automated capillary sequencer (ABI 3730; Applied Biosystems Deutsch-
land GmbH). An additional 24 CAKUT patients were only screened for
mutations in the CHD1L exons 18, 19 and 21, in which missense variants
had been identified, because there was not enough DNA available to ana-
lyse the entire coding region. The effects of the detected missense variants
were analysed with the web-based prediction programme PolyPhen
(http://genetics.bwh.harvard.edu/pph/index.html). When available, parental
DNA samples were specifically analysed for the variant found in their child.
Primer sequences and PCR conditions are available upon request. Nucleotide
numbering of the CHD1L variants reflects complementary DNA (cDNA)
numbering in the GenBank reference sequence NM_004284, and11 corre-
sponds to the A of the ATG translation initiation codon.
Tissue-specific messenger RNA expression analysis
To test for tissue-specific expression of theCHD1L gene, we used the Human
Multiple Tissue cDNA (MTC) Panels I and II and the Human Digestive
System MTC panel for fetal tissues (Clontech—Takara Bio Europe, Saint
Germain-en-Laye, France). In the MTC panels, fetal cDNAs were pooled
from 13 to 59 spontaneously aborted Caucasian fetuses aged 16–37 weeks.
Relative quantifications in real-time experiments were performed on the ABI
Prism 7900HT Fast Real-Time PCR System (Applied Biosystems Deutsch-
land GmbH) using the inventoried TaqMan Gene Expression Assay for
theCHD1L gene (Applied Biosystems Deutschland GmbH). Each sample
was normalized to the TaqMan Endogenous Control Beta-2-Microglobu-
lin (Applied Biosystems Deutschland GmbH), and comparative Ct quan-
tification [delta–delta (DD)Ct] was applied. The expression of theCHD1L
gene in the other tissues was calculated relative to the expression in the
fetal kidney, which was arbitrarily defined as 1. Each sample was assayed
in triplicate.
Immunohistochemistry of renal sections
Immunohistochemical analysis of tissue samples (5 lm sections mounted
on Superfrost slides) was performed essentially as described previously
[23, 24]. Briefly, sections were deparaffinized in histoclear or xylene and
dehydrated through a series of graded alcohols prior to blocking endoge-
nous peroxidase. For antigen retrieval, slides were boiled in 0.01 M citrate
buffer (pH 6.0) using a microwave (1 3 10 min or 3 3 8 min, 450 W).
Unspecific binding sites and endogenous biotin were saturated [10% fetal
calf serum (FCS)/1% bovine serum albumin or 10% horse serum and
avidin in phosphate-buffered saline (PBS); Vector Laboratories, Burlin-
game, CA; 20 min at room temperature] prior to incubation (4C, over
night) with the specific antibody [CHD1L, rabbit polyclonal IgG pur-
chased from Atlas Antibodies (Catalog Number HPA 028 670; diluted
1:300 for postnatal and 1:500 for embryonal sections), Stockholm,
Sweden; megalin (proximal tubule), rabbit polyclonal antiserum
(1:100; Santa Cruz Biotechnology Inc., Heidelberg, Germany); Tamm–
Horsfall protein (THP, thick ascending limb of Henle’s loop and distal
tubule), rabbit polyclonal antiserum (1:500; Santa Cruz Biotechnology);
aquaporin-2 (collecting duct), rabbit polyclonal antiserum (1:100; Santa
Cruz Biotechnology)]. Subsequently, slides were treated with a biotin-
labelled secondary antibody (Vector Laboratories) prior to incubation with
peroxidase-conjugated avidin–biotin complexes (Vectastain Elite ABC
kit; Vector Laboratories) and 3,3#-diaminobenzidine (Merck KG, Darm-
stadt, Germany; tablets of 10 mg). Counterstaining was carried out with
haematoxylin. Slides derived from renal cell carcinoma were used as
positive controls for CHD1L expression. For negative controls, the specific
antibody was replaced by an unrelated antibody of the same subclass
(isotype control). Slides were examined with a Zeiss Axiophot II (Jena,
Germany) or a Leica DMI 4000 microscope (Wetzlar, Germany) equipped
with a digital camera (DFC 320 R2; Leica).
CHD1L expression constructs
The generation of the full-length human wild-type CHD1L expression
construct has been described elsewhere, and this construct was kindly
provided by Zuzana Horejsi and Simon J. Boulton from the DNA Damage
Response Laboratory, Clare Hall, London Research Institute, South
Mimms, EN6 3LD, UK [16].
The three identified missense variants, Gly700Arg (exon 18), Ile765Met
(exon 19) and Ile827Val (exon 21), were introduced into wild-type CHD1L
by PCR mutagenesis with primers (Metabion, Martinsried, Germany) con-









CAGGTTGTCTTCCCAACTTGC-3#) and appropriate restriction enzymes
for subcloning. Each amplicon was introduced as a 657-bp PpuMI/XbaI
(Fermentas Life Sciences, Burlington, Canada) restriction fragment into
PpuMI/XbaI digested wild-type CHD1L (untagged).
The myc-tagged full-length human wild-type CHD1L construct was gen-
erated by amplification of the provided untagged wild-type CHD1L plasmid
with primers containing the appropriate restriction sites and lacking the stop
codon (CHD1L_KpnI_forward: 5#-GCTGACGGTACCGACATGGAGCG
CGCGGGCGCT-3#, CHD1L_EcoRV_reverse: 5#-ctggatatcagcttctgct-
cAGGCACCAGCTGTCTTGAGGAGG-3#) and introduced as a 2.7-kb
KpnI/EcoRV restriction fragment into the eukaryotic expression vector
pcDNA3.1/myc-His (Invitrogen by Life Technologies, Carlsbad, CA) con-
taining a C-terminal myc and poly-His tag. The three missense variants,
Gly700Arg, Ile765Met and Ile827Val, were amplified from the newly gen-
erated CHD1L constructs containing the corresponding variant with the
primers CHD1L-forward: 5#-GCCAAGAGAAGGAGACTCATAGAGG-
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3# and CHD1L_EcoRV_reverse: 5#-ctggatatcagcttctgctcAGGCACCAGCT
GTCTTGAGGAGG-3# and in each case introduced as a 620-bp PpuMI/
EcoRV restriction fragment into the PpuMI/EcoRV digested pcDNA3.1
wild-type CHD1L myc-tagged construct. All constructs were verified by
sequencing.
Cell culture and transfection
Human embryonic kidney (HEK) 293T cells were grown in Dubecco’s
modified Eagle’s medium (Gibco/Invitrogen) with 10% FCS and seeded
1 day prior to transfection. Cells were transiently transfected with 750 ng
(100 lL Optimem, 2.5 lL Fugene) and 4 lg (400 lL Optimem, 12 lL
Fugene) of myc-tagged wild-type and mutant CHD1L constructs, respec-
tively, using Fugene HD Transfection Reagent according to the man-
ufacturer’s instructions (Roche Diagnostics, Grenzach, Germany).
Twenty-four hours after transfection, cells were lysed with 0.05 M
HEPES supplemented with 1 mM dithiothreitol (DTT).
Immunoprecipitation of myc-tagged CHD1L proteins
For immunoprecipitation (IP) with anti-c-myc-conjugated agarose beads
(Sigma Aldrich, St. Louis, MO), the ratio of protein lysate (in microgram)
to anti-c-myc agarose (in microlitre) was 1:5. For each cell lysate, a sus-
pension of anti-c-myc-conjugated agarose was settled in a microcentrifuge
tube by a short spin (30 s at 8000 g), the supernatant was removed and the
resin was washed three times with 150 lL 13 PBS. Subsequently, the
respective cell lysate was added, and the final volume was brought to at
least 200 lL with 13 PBS. The suspension of anti-c-myc agarose and cell
lysate was incubated for 2.5 h on an orbital shaker at 4C. Afterwards, the
resin was pelleted by centrifugation and was washed twice with 150 lL
13 PBS. Finally, the supernatant was aspirated, except ~10 lL which
were left above the agarose. For western blot analysis, 0.05 M HEPES
buffer containing 1 mM DTT and 23 sodium dodecyl sulphate (SDS)
sample buffer containing 400 mM DTT were added in a ratio of 1:1,
and the samples were denatured for 5 min at 95C.
Western blot analysis
Samples were used in equal amounts for SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE; SE 600 Ruby; GE Healthcare, Freiburg, Germany).
Proteins were blotted on a polyvinylidine difluoride membrane (Amersham
Hybond-P; GE Healthcare) using a semi-dry transfer unit (TE77 ECL; GE
Healthcare). The myc-tagged wild-type and mutant CHD1L proteins were
detected using a mouse anti-c-myc monoclonal antibody (Santa Cruz Bio-
technology Inc.), PARP1 using a rabbit anti-PARP1 polyclonal antibody
(Abcam, Cambridge, UK) and b-actin using a rabbit anti-b-actin monoclo-
nal antibody (Sigma Aldrich), each followed by incubation with horseradish
peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies (Santa Cruz
Biotechnology Inc.). Blots were developed using a chemiluminescent de-
tection kit (Applichem, Darmstadt, Germany). Western blot bands were
quantified using the NIH ImageJ software.
Immunofluorescence
HEK 293T cells, which were transiently transfected with empty
pcDNA3.1/myc-His expression vector (mock) or wild-type or mutant
CHD1L constructs, were seeded on coverslips before fixation with 4%
wt/vol paraformaldehyde, permeabilization with 0.1% Triton X-100 and
blocking with 5% fat-free milk powder/0.1% Triton X-100/1% goat
serum. CHD1L was detected via a primary rabbit anti-CHD1L polyclo-
nal antibody (1:750; Atlas Antibodies) and a secondary goat anti-rabbit
Alexa Fluor 568 labelled antibody (1:350; Invitrogen). Alexa Fluor 488
phalloidin (1:40; Invitrogen), which specifically detects F-actin, was
used to visualise actin filaments within the cytoplasm. Nuclei were
visualised with 4’,6-diamidino-2-phenylindole counterstain. Fluores-
cent images were captured using a Leica DMRXA2 epifluorescence
microscope.
Results
CHD1L mutation analysis in CAKUT patients
Sequencing of the entire coding region of the CHD1L gene
in 61 CAKUT patients and of the CHD1L exons 18, 19 and
21 in 24 additional CAKUT patients revealed three differ-
ent heterozygous missense variants. The variant found in
Patient 1 (whose parents were not available for genetic
testing) was a guanine-to-adenine transition at nucleotide
position 2098 in exon 18 leading to a glycine-to-arginine
substitution (c.2098G>A;p.Gly700Arg). The Gly700Arg
variant was not found in 440 control chromosomes from
central European individuals and was predicted to be prob-
ably damaging using the web-based PolyPhen software.
The variant found in Albanian Patient 2 (inherited from
his mother, who had no kidney or urinary tract anomalies
on ultrasound) was an adenine-to-guanine transition at nu-
cleotide position 2295 in exon 19 leading to an isoleucine-
to-methionine substitution (c.2295A>G;p.Ile765Met).
The Ile765Met variant was found in one of 430 control
chromosomes from central European blood donors in
whom a subtle CAKUT phenotype was not excluded,
but not in 136 control chromosomes from Albanian indi-
viduals, and was predicted to be possibly damaging. The
variant found in Patient 3 (inherited from his father, who
was not available for examination by renal ultrasound)
was an adenine-to-guanine transition at nucleotide posi-
tion 2479 in exon 21 leading to an isoleucine-to-valine
substitution (c.2479A>G;p.Ile827Val). The Ile827Val
variant was not found in 402 control chromosomes from
central European individuals and was predicted to be be-
nign (Figure 1). All affected amino acids are conserved
(p.Ile765) or highly conserved (p.Gly700 and p.Ile827) in
higher animals.
CHD1LmessengerRNAexpression indifferenthuman tissues
To further investigate whether CHD1L is associated with
the CAKUT phenotype, we quantified the messenger RNA
(mRNA) levels of CHD1L in various fetal and adult tissues
including the kidney (Figure 2). CHD1L was expressed in
all analysed tissues. In the fetus, CHD1L expression was
highest in brain followed by kidney and then by muscle,
liver, thymus, lung, heart and spleen. Testis showed the
highest CHD1L mRNA expression level of all adult tissues
(data not shown). Fourfold less expression was measured in
adult brain, followed by liver, muscle, pancreas, small in-
testine, ovary, kidney, colon, prostate, placenta, heart, lung,
spleen and leukocytes. The CHD1L mRNA levels in fetal
kidney were approximately four times higher than in adult
kidney. Thus, among all corresponding fetal and adult tis-
sues investigated, the fetal to adult expression ratio was
highest in the human kidney.
Localization of the CHD1L protein in the normal human
developing kidney
At 7 weeks gestation, the developing metanephric kidney
consists of the central epithelial ureteric bud, with numerous
peripheral branches that will give rise to the adult collecting
ducts and collecting system and two types of mesenchyme:
loose mesenchyme that will form stroma of the mature organ
and condensing or condensed mesenchyme adjacent to the
bud tips which undergoes mesenchymal-to-epithelial trans-
formation to form the remainder of the nephrons from glo-
merulus to distal tubules. During the latter process, this
‘induced’ mesenchyme goes through vesicle, comma- and
2358 A. Brockschmidt et al.
S-shaped body stages before the first identifiable glomeruli
and tubule segments can be discerned. The first site with
identifiable CHD1L immunoreactivity was the ureteric bud,
where protein was detected in rare cells in early cortical bud
branches, although not in the more mature medullary seg-
ments. At later stages from 8 to 11 weeks, sporadic staining
of individual cells was detected in loose mesenchyme, but
strongly immunoreactive CHD1L was detected as mesen-
chyme condensed, with clear expression in early nephron
precursors. Occasional positive cells were still detected in
the ureteric bud, predominantly in the outer cortex where
the bud was in intimate contact with the condensing mesen-
chyme. Subcellular localization was mainly nuclear, although
a cytoplasmic signal could not be ruled out in some cells.
Positive cells were also observed in some more mature struc-
tures, such as fully formed glomeruli or tubular structures
(Figure 3). By immunofluorescence, CHD1L was exclusively
localized to the nucleus of HEK cells (Figure 3). The subcel-
lular localization of mutant CHD1L in HEK cells transfected
with constructs expressing variant CHD1L was nuclear and
thus not different from endogenous CHD1L or after wild-type
CHD1L transfection (data not shown).
Localization of the CHD1L protein in the normal human
postnatal kidney
In the normal kidney from a 5-year-old boy (autopsy ma-
terial), CHD1L was immunolocalized to tubular cells in all
segments of the tubule system. This was verified by stain-
ing of parallel sections with established markers of the
tubular system, i.e. megalin for the proximal tubule, THP
for the Henle loop and aquaporin-2 for the distal tubule and
collecting duct. CHD1L staining was mainly detected in
the cytoplasm and to a lesser extent in the nuclei of normal
tubule cells (Figure 4).
Fig. 1. Identification of CHD1L variants in CAKUT patients. Pedigrees and electropherograms of the three patients with the CHD1L missense variants:
CHD1L,c.2098G>A;p.Gly700Arg (exon 18), CHD1L,c.2295A>G;p.Ile765Met (exon 19) and CHD1L,c.2479A>G;p.Ile827Val (exon 21). The
affected nucleotide positions in the electropherograms are marked by arrows (A). Genomic location of the three missense variants within the CHD1L
gene: CHD1L,c.2098G>A;p.Gly700Arg (exon 18), CHD1L,c.2295A>G;p.Ile765Met (exon 19) and CHD1L,c.2479A>G;p.Ile827Val (exon 21) rela-
tive to the functional Snf2 family N-terminal domain (SNF2_N), the helicase superfamily C-terminal domain (Helic_C) and the macro domain (Macro) of
the CHD1L protein. Note that all variants are localized close to or within the macro domain (B).
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CHD1L protein expression in the kidney and hydroureter
from Patient 2
In the hydronephrotic kidney removed from Patient 2 at age
16 years prior to transplantation (nephrectomy material),
CHD1L was also immunolocalized to tubular cells
throughout the nephron. Although Patient 2 was older at
nephrectomy than our healthy control, the intensity of
CHD1L staining in the tubules appeared to be higher in
the hydronephrotic kidney compared to the normal kidney.
CHD1L staining was preferentially nuclear in the hydro-
nephrotic kidney and in the corresponding hydroureter,
where nuclear CHD1L expression was seen throughout
the urothelium (Figure 4).
Interaction of mutant CHD1L protein with PARP1
To elucidate the functional effect of the three CHD1L var-
iants with respect to their interaction with PARP1, we
transfected HEK293T cells with c-myc-tagged wild-type
and mutant CHD1L constructs. After cell lysis, IP of
c-myc-tagged CHD1L protein was performed with anti-
c-myc-conjugated agarose beads, followed by protein sep-
aration using SDS–PAGE. Western blot analysis with an
anti-b-actin antibody demonstrated successful IP: b-actin
signals were detectable in the input but not after IP (data not
shown). PARP1 was immunoprecipitated together with
CHD1L wild-type and mutant proteins and detected
with an anti-PARP1-antibody, while immunoprecipitated
c-myc-tagged wild-type and mutant CHD1L was detected
with an anti-c-myc antibody. Visual inspection of western
blot bands after IP showed that the signals for PARP1 in
relation to the c-myc signals were clearly decreased in all
mutants compared to wild-type CHD1L (Figure 5A).
Western blot bands were quantified using the NIH ImageJ
software. The PARP1 and the respective c-myc Western blot
signals after IP were measured, and the ratio of both signals
was calculated to compare the interaction of PARP1 with
wild-type and mutant CHD1L (Figure 5B). When averaging
the results from three independent experiments, CHD1L and
PARP1 interaction was diminished ~1.9-fold in variant
Gly700Arg, ~2.3-fold in variant Ile765Met and ~2.2-fold
in variant Ile827Val as compared to wild-type CHD1L.
Discussion
In this study, we describe heterozygous missense variants
in the CHD1L gene in three male patients with a CAKUT
phenotype characterized by uni- or bilateral hypodysplastic
kidneys or hydronephrosis due to obstructive megaureters.
Both patients with bilateral CAKUT had severe kidney
failure requiring renal replacement therapy from age 9 or
13 years, respectively. The patient with unilateral hypodys-
plasia had a compensatory hypertrophy of the other kidney
so that renal function was normal when he was last exam-
ined at 6 years of age. Two of the three variants in CHD1L
were inherited from a parent, one of whom had a normal renal
tract on ultrasound and the other being unavailable for sono-
graphic examination. The parents of the third patient were not
available for genetic testing, so inheritance or de novo occur-
rence could not be ascertained. Reduced penetrance and var-
iable expressivity are not unusual in CAKUT; aberrations in
thePAX2,EYA1, SIX1 andHNF1B/TCF2 genes cause highly
variable and even missing renal phenotypes [9, 25].
There are various lines of evidence suggesting that the de-
tected missense variants in CHD1L could be associated with
the CAKUT phenotype in the patients of the present study.
Firstly, two variants were not detected in at least 400 control
chromosomes indicating a frequency of much <1% of these
variants in the general population. The Albanian patient’s
missense variant was not found in 136 control chromosomes
from Albanians, but in 1 of 430 control chromosomes from
central Europeans, in whom a subtle CAKUT phenotype can-
not be excluded because renal ultrasound was not routinely
performed. Secondly, using the web-based PolyPhen soft-
ware, two of the three variants were predicted to be probably
or possibly damaging, while only one of the variants was
predicted to be benign. This software tool predicts the possible
impact of an amino acid substitution on the structure and
function of a human protein using physical and comparative
considerations but does not invariably have to be correct.
Further evidence for a role of CHD1L in kidney develop-
ment came from quantitative mRNA analysis. The CHD1L
gene was strongly expressed in the fetal human kidney, and
the renal fetal to adult expression ratio (4:1) was highest
compared to all other tissues tested, suggesting that CHD1L
expression is of particular importance in the developing kid-
ney. By immunohistochemistry of human embryonal sec-
tions with a CHD1L-specific antibody, we demonstrated
that CHD1L immunolocalized in the early ureteric bud
and in early nephron precursors from 7 through 11 weeks
of gestation. For normal kidney development, mutual induc-
tion from the tips of the ureteric bud to the adjacent meta-
nephric mesenchyme is essential, the sites in which CHD1L
immunoreactivity was strongest. The bud lineage develops
into the collecting system while induced mesenchyme
undergoes comma- and S-shaped body morphological stages
en route to forming the nephrons from glomerulus to distal
tubule [26, 27]. The fact that CHD1L is expressed in both the
Fig. 2. Quantitative expression of CHD1L mRNA in human fetal
and adult tissues. Expression levels were determined by real-time reverse
transcription–PCR, normalized to beta-2-microglobulin mRNA expres-
sion and displayed relative to the CHD1L mRNA expression in the fetal
kidney. CHD1L mRNA expression was the second highest in the fetal
kidney compared to the other fetal tissues analysed and was four times as
high in fetal compared to adult kidneys. Testis showed the highest CHD1L
mRNA expression level of all adult tissues (data not shown).
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ureteric bud and the metanephric mesenchyme may explain
the different CAKUT phenotypes observed in patients
with CHD1L variants, i.e. hydronephrosis secondary to ob-
structive megaureters, a malformation primarily of the ure-
ter, and renal hypodysplasia, an anomaly primarily of the
nephron.
While in human embryonal kidney cells, CHD1L was
mainly detectable in the nucleus, in the kidneys from a 5-
year-old child, CHD1L immunolocalized preferentially in
the cytoplasm and only rarely to the nuclei of tubular cells
in all parts of the mesenchyme-derived nephron. Interest-
ingly, in the tubular cells and urothelium of the hydro-
nephrotic kidney and hydroureter removed at the age of 16
years from Patient 2, the CHD1L expression seemed to be
higher than in the normal kidney of the younger child
recapitulating fetal levels, compatible with a lack of ter-
minal nephron differentiation described in CAKUT. In the
developing human kidney and the malformed kidney and
ureter, CHD1L expression was predominantly nuclear, in
line with recent reports that CHD1L is a chromatin-
remodelling enzyme that catalyses nucleosome sliding
and can act as a DNA damage response protein rapidly
recruited to DNA damage sites in the nucleus [16, 17].
Chromatin remodelling is required for normal develop-
ment in mammalian cells to orchestrate spatiotemporally
distinct gene expression programmes necessary for cellu-
lar differentiation [18, 19]. Thus, the CHD1L variants
identified here may induce deficits in differentiation in
tubular cells of the kidney and in the urothelium due to
impaired chromatin remodelling.
Fig. 3. Expression of CHD1L in developing human kidneys. Immunohistochemistry for CHD1L in 8–11 weeks human embryonal kidneys (A–D). All
sections were counterstained with haematoxylin; positive immunohistochemical signal is brown; in control samples, 10% FCS was substituted for the
primary antibody. Control panel from 8-week-old embryo demonstrating lack of background staining and illustrating early renal development with
ureteric bud (u) and stages of nephron formation from comma shaped bodies through developing glomeruli (A). Nearby section demonstrating positive
nuclear staining in the nephrogenic zone around the periphery of the kidney, where new nephrons are being formed (B). Control higher power view from
11 weeks showing ureteric bud, ureteric bud tip (t) and developing glomeruli (g), with loose mesenchyme (dotted arrow) and condensed mesenchyme
(solid arrow) (C). Nuclear CHD1L was predominantly detected in condensed mesenchyme, although occasional positive cells were detected at the very
tips of the ureteric bud (i.e. adjacent to the condensing mesenchyme) and in loose mesenchyme; fully formed glomeruli and deeper, more mature tubule
segments were negative (not shown) (D). Immunofluorescence for CHD1L in HEK cells (E–H). CHD1L was stained for using a primary rabbit anti-
CHD1L polyclonal antibody and a secondary goat anti-rabbit Alexa Fluor 568 labelled antibody (E), 4’,6-diamidino-2-phenylindole was used as
counterstain to delineate the nucleus (F), filamentous actin was visualized in the cytoplasm and at the cell membrane using Alexa488-phalloidin (G).
The merged image clearly demonstrates the nuclear localization of CHD1L in embryonal cells (H).
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Impaired chromatin remodelling could alter the expression
of key factors in renal system development such as glial-
derived neurotrophic factor (GDNF), which is secreted by
the metanephric mesenchyme and mediates ureteric bud in-
duction from the nephric duct, and the RET receptor tyrosine
kinase expressed in the ureteric bud to induce branching [28,
29]. In particular, the transcriptional fine tuning of factors
regulating GDNF levels and spatial expression [30, 31] and
the factors regulating RET [32–34] could be compromised by
impaired chromatin remodelling due to mutated CHD1L. The
dysregulated expression of the genes important for renal sys-
tem development could cause aberrant interactions between
the ureteric bud and the metanephric mesenchyme, which is
known to cause renal hypodysplasia [27].
Strong evidence that mutations in a chromatin-remodelling
enzyme can play a role in human renal tract anomalies comes
from the CHD7 gene, an ATP-dependent chromatin remod-
eller with structural homologies to CHD1L [11]. Mutations in
CHD7 cause CHARGE syndrome [20], which is associated
with renal tract anomalies, such as horseshoe kidneys, renal
agenesis, VUR and renal cysts, in ~20% of patients carrying
CHD7 mutations [22]. Likewise, in an animal model, a het-
erozygous mutation in Chd2, another member of the Snf2-
like group of ATPases that function in chromatin remodel-
ling, results in a complex renal phenotype consisting of glo-
merulopathy, proteinuria and significantly impaired kidney
function in ~85% of mice [35, 36].
The hypothesis that the CHD1L mutations identified in
CAKUT patients may impair chromatin remodelling is
further substantiated by the fact that all variants resulted
in amino acid substitutions within or close to the macro
domain of the CHD1L protein. The intact C-terminal
macro domain binds PAR and interacts with chromatin-
associated PARP1 in vitro [16, 17]. PARP1 localizes to a
large fraction of active promoters with a distinct role in
determining gene expression [37] and strongly activates
CHD1L ATPase- and chromatin-remodelling activities
[17]. By pull-down assay of transfected cell lysates, we
Fig. 4. Detection of megalin, THP and aquaporin-2 in normal human postnatal kidney (left panel) and of CHD1L in healthy and diseased specimens
(right panel). Sections were probed with mAbs specific for megalin (A), THP (B), aquaporin-2 (C) and CHD1L (D–F) [normal kidney of 5-year-old (D);
hydronephrotic kidney of 16-year-old Patient 2 with hypofunctional CHD1L variant (E); hydroureter from same patient (F)]. Bound antibody was
visualized using biotin-labelled secondary antibody in combination with peroxidase-conjugated avidin–biotin complex and 3,3#-diaminobenzidine as
substrate. Magnification:3100 (bar: 200 lm) (A–E),325 (bar: 1 mm) (F) and3400 (bar: 50 lm) (inserts in D–F). In normal postnatal sections, CHD1L
was expressed in the cytoplasm of tubuloepithelial cells in all segments of the tubule system. CHD1L expression appeared higher in the dysplastic tubules
of Patient 2 with a hypofunctional CHD1L variant than in normal kidneys, recapitulating high fetal levels, and was predominantly nuclear in tubular cells
and urothelium of hydronephrotic kidney and hydroureter.
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found that all three CHD1L variants detected in our CA-
KUT patients showed decreased PARP1 interaction com-
pared to wild-type CHD1L. These data suggest that the
CHD1L variants identified may be hypofunctional and
that the reduced interaction with PARP1 may compro-
mise CHD1L ATPase- and chromatin-remodelling activ-
ities. This has recently been shown for CHD1L mutants in
which the macro domain was deleted and for the specific
macro domain Asp723Ala mutant [16, 17]. Interestingly,
in this mutant, the amino acid substitution is located in
the N-terminal part of the macro domain between
Gly700Arg and Ile765Met, two variants identified here.
The CHD1L macro domain deletion mutants and the As-
p723Ala mutant showed no or decreased interaction with
PAR and PARP1, and the recruitment of the Asp723Ala
mutant to DNA damage sites was severely impaired, in-
dicating at least a partial loss of function when the macro
domain is deleted or altered at certain residues [16, 17]. If
interaction with PARP1 is decreased like in the variants
detected here, this functional deficit should have an im-
pact on the ATPase- and chromatin-remodelling activities
of CHD1L because they are strongly stimulated by
PARP1 [16].
Conclusion
In summary, our study provides evidence that the ATP-
dependent chromatin-remodelling enzyme CHD1L may
play a role in renal development and in congenital anomalies
of the kidneys and the urinary tract when altered. These
conclusions are based on the following novel findings: (i)
CHD1L expression was high in fetal kidneys and was four
times higher in fetal compared to adult kidney. (ii) CHD1L
immunolocalized in the early ureteric bud and early nephron
precursors, critical stages of kidney development, in which
CHD1L expression was predominantly nuclear and in the
cytoplasm of tubule cells in the normal postnatal kidney. (iii)
Heterozygous missense variants in CHD1L were detected in
3 of 85 CAKUT patients analysed, all leading to amino acid
substitutions within or near the macro domain necessary for
interaction with PAR and PARP1. (iv) Mutant CHD1L was
hypofunctional with respect to interaction with PARP1. (v)
The hydronephrotic kidney from a 16-year-old CAKUT pa-
tient with a hypofunctional CHD1L variant showed high
nuclear CHD1L expression in dysplastic tubule cells mim-
icking the embryonal situation, compatible with a lack of
terminal nephron differentiation described in CAKUT.
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